URGENT: Court Ruling on Tariffs — Implications for Medtech
Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!
Emerging Policy Response Resources
2025 Emerging Policy Response Resources
Swiss Medtech andAdvaMed® Call for Zero for Zero Tariffs and Recognition of FDA Approvals and Clearances
Bern/Washington – Swiss Medtech, the leading trade association for medical technology companies in Switzerland, andAdvaMed®, the U.S. Medtech Association and the world’s largest organization representing medtech innovators, are jointly calling…
Executive Overview_Kennedy v. Braidwood Management, Inc.
The U.S. Supreme Court is reviewing Braidwood Management v. Becerra, a high-stakes case challenging the authority of the U.S. Preventive Services Task Force (USPSTF) under the Affordable Care Act. At…
AdvaMed® Testifies in U.S. Senate
WASHINGTON – Today, President and CEO Scott Whitaker of AdvaMed, the MedTech Association®, testified before the U.S. Senate Committee on Finance in its hearing focused on the impact of tariffs…
AdvaMed® Comments to OMB Deregulation RFI
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
AdvaMed®, U.K. Medtech Association Call for Flexibility on Tariffs, “Regulatory Convergence”
WASHINGTON—AdvaMed, the MedTech Association®, the world’s largest organization representing medtech innovators, and the Association of British HealthTech Industries (ABHI), the leading trade association for medical technology companies in the United…
Why Lifesaving Medtech Should Be Tariff-free: An Interview with AdvaMed’s CEO
AdvaMed® President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential,…
AdvaMed® CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners
WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the MedTech Association®, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for…
Why the Administration Should Be Flexible with Medtech Tariffs to Protect Patients and Innovation
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
Tariffs: Understanding the Nairobi Protocol and related Customs Procedures
Learn how the Nairobi Protocol may support duty-free access for medical devices under new tariffs.